Christy Hong

Christy Hong

Auto-generated profile, based on publicly available information

Christy Hong

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Science
Verified
Journal Article
Closed access
MBMelody Di Bona
Melody Di Bona
YCYanyang Chen
Yanyang Chen
AAAlbert S. Agustinus
Albert S. Agustinus
AMAlice Mazzagatti
Alice Mazzagatti
MDMercedes A. Duran
Mercedes A. Duran
SBSamuel F. Bakhoum
Samuel F. Bakhoum
Chromosome-containing micronuclei are a hallmark of aggressive cancers. Micronuclei frequently undergo irreversible collapse, exposing their enclosed chromatin to the cytosol. Micronuclear rupture catalyzes chromosomal rearrangements, epigenetic abnormalities, and inflammation, yet mechanisms safeguarding micronuclear integrity are poorly understood. In this study, we found that mitochondria-derived reactive oxygen species (ROS) disrupt micronuclei by promoting a noncanonical function of charged multivesicular body protein 7 (CHMP7), a scaffolding protein for the membrane repair complex known as endosomal sorting complex required for transport III (ESCRT-III). ROS retained CHMP7 in micronuclei while disrupting its interaction with other ESCRT-III components. ROS-induced cysteine oxidation stimulated CHMP7 oligomerization and binding to the nuclear membrane protein LEMD2, disrupting micronuclear envelopes. Furthermore, this ROS-CHMP7 pathological axis engendered chromosome shattering known to result from micronuclear rupture. It also mediated micronuclear disintegrity under hypoxic conditions, linking tumor hypoxia with downstream processes driving cancer progression.

2 October 2025 in Cancer Discovery
Verified
Journal Article
Closed access
YBYang Bai
Yang Bai
AAAlbert S. Agustinus
Albert S. Agustinus
SYShira Yomtoubian
Shira Yomtoubian
CMCem Meydan
Cem Meydan
DMDylan R. McNally
Dylan R. McNally
VMVivek Mittal
Vivek Mittal
Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. Here, we uncover a direct role for EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer. Across breast cancers, EZH2 expression correlates with copy-number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacologic EZH2 inhibition suppresses CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified tankyrase (TNKS), a PARP, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts centrosomal P4.1–associated protein (CPAP), driving centrosome overduplication, multipolar mitosis, and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the antimetastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints. Significance: We elucidate epigenetic regulation of CIN through EZH2–TNKS–CPAP-axis and show that CIN suppression is important for the efficacy of EZH2 inhibition on metastasis. These mechanistic insights are informative for developing CIN-suppressing therapies.

4 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMichael Schubert
Michael Schubert
CHChristy Hong
Christy Hong
LJLaura Jilderda
Laura Jilderda
MRMarta Requesens Rueda
Marta Requesens Rueda
ATAndréa E. Tijhuis
Andréa E. Tijhuis
FFFloris Foijer
Floris Foijer
Chromosomal instability is a hallmark of cancer, but also an instigator of aneuploidy-induced stress, reducing cellular fitness. To better understand how cells with CIN adjust to aneuploidy and adopt a malignant fate in vivo , we performed a genome-wide mutagenesis screen in mice. We find that specifically aneuploid tumors inactivate Stat1 signaling in combination with increased Myc activity. By contrast, loss of p53 is common, but not enriched in CIN tumors. Validation in another tissue type confirmed that CIN promotes immune cell infiltration, which is alleviated by Stat1 loss combined with Myc activation, but not with p53 inactivation, or Myc activation alone. Importantly, we find that this mechanism is preserved in human aneuploid cancers. We conclude that aneuploid cancers inactivate Stat1 signaling to circumvent immune surveillance.

10 September 2026
Verified
Other
Open access
YBYang Bai
Yang Bai
AAAlbert S. Agustinus
Albert S. Agustinus
SYShira Yomtoubian
Shira Yomtoubian
CMCem Meydan
Cem Meydan
DMDylan R. McNally
Dylan R. McNally
VMVivek Mittal
Vivek Mittal
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.

12 January 2026
Verified
Other
Open access
YBYang Bai
Yang Bai
AAAlbert S. Agustinus
Albert S. Agustinus
SYShira Yomtoubian
Shira Yomtoubian
CMCem Meydan
Cem Meydan
DMDylan R. McNally
Dylan R. McNally
VMVivek Mittal
Vivek Mittal
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.

12 January 2026
Verified
Other
Open access
YBYang Bai
Yang Bai
AAAlbert S. Agustinus
Albert S. Agustinus
SYShira Yomtoubian
Shira Yomtoubian
CMCem Meydan
Cem Meydan
DMDylan R. McNally
Dylan R. McNally
VMVivek Mittal
Vivek Mittal
Table S1 shows Overlap of differential regulated genes in EZH2high vs EZH2low and EZH2i vs vehicle of EZH2high cells comparisons identifies 12 common genes.